Therefore, manipulating ILC subsets in AT, which includes promoting appropriate activation and expansion of ILC2s and inhibiting excessive proliferation of ILC1s may offer new therapeutic avenues for obesity-related diabetes. The gene discussed is CCL27; the disease is diabetes mellitus.